Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 4/20 | 0.52 |
| ▸ | FLT1 | P17948 | 3/20 | 0.52 |
| ▸ | FLT4 | P35916 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | VCP | P55072 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1218609 | 0.83 | NOTUM (0.59) | ALOX15TSHRCASP1RAB9ANPC1 | |
| SCHEMBL23539672 | 0.80 | VCP (0.55) | TSHRRAB9ANPC1NOTUMVCP | |
| SCHEMBL30041533 | 0.80 | VCP (0.55) | TSHRRAB9ANPC1NOTUMVCP | |
| SCHEMBL29313904 | 0.79 | NOTUM (0.43) | ALOX15TSHRCASP1RAB9ANPC1 | |
| SCHEMBL3638292 | 0.79 | NPC1 (0.53) | ALOX15TSHRCASP1RAB9ANPC1 | |
| SCHEMBL15115337 | 0.79 | NPC1 (0.54) | ALOX15TSHRCASP1RAB9ANPC1 | |
| SCHEMBL17965556 | 0.79 | NPC1 (0.53) | ALOX15TSHRCASP1RAB9ANPC1 | |
| SCHEMBL23539907 | 0.79 | PTPN1 (0.54) | RAB9ANPC1HPGDMEN1KMT2A | |
| SCHEMBL5186343 | 0.77 | HSD17B1 (0.58) | ALDH1A1HPGDMEN1KMT2AVCP | |
| SCHEMBL26307287 | 0.77 | FLT1 (0.49) | TSHRRAB9ANPC1NOTUMKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023244788-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-5646169-A | ADMINISTERING SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES TO HUMANS OR OTHER MAMMALS | BEECHAM GROUP P.L.C. (GB) | 1997-07-08 | — | — | US | disclosed |
| US-5643933-A | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G. D. SEARLE & CO. (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1996038442-A1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-12-05 | — | — | WO | disclosed |
| US-5521201-A | SUBSTITUTED-THIAZOLIDINEDIONE DERIVATIVES | BEECHAM GROUP P.L.C. | 1996-05-28 | — | — | US | disclosed |
| US-5260445-A | Hypoglycemic | BEECHAM GROUP P.L.C. (GB) | 1993-11-09 | — | — | US | disclosed |
| US-5232925-A | Treating hypertension | BEECHAM GROUP P.L.C. (GB) | 1993-08-03 | — | — | US | disclosed |
| US-5194443-A | Thiazolinediones, Hypoglycemic Agents, Antilipemic Agents | BEECHAM GROUP P.L.C. (GB) | 1993-03-16 | — | — | US | disclosed |
| US-5002953-A | Substituted Thiazolidinedione Derivatives | BEECHAM GROUP P.L.C. (GB) | 1991-03-26 | — | — | US | disclosed |
| EP-0306228-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1989-03-08 | — | — | EP | disclosed |
| US-4143047-A | 2-SULFINYL AND 2-SULFONYL OXAZOLES | LILLY INDUSTRIES LIMITED (GB) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | ALOX15 3342/4885TSHR 4380/4885CASP1 1217/4885 |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | ALOX15 3342/4885TSHR 4380/4885CASP1 1217/4885 |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | ALOX15 3189/4885TSHR 1149/4885CASP1 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.